22 February 2021
Visiongain has published a new report on Antisense and RNAi Therapeutics Market Report to 2031. According to the Visiongain analysis, the global Antisense and RNAi Therapeutics market is anticipated to grow at a CAGR of XX% during the forecast period (2021-2031). The global Antisense and RNAi Therapeutics market is segmented by technology (RNA Interference, Antisense RNA), by application (Oncology, Cardiovascular Diseases (CVDs), Infectious Diseases, Genetic Disorders, Others), by administration (Pulmonary Delivery, Intravenous Injections, Intra-dermal Injections, Others). By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). The report includes detailed Profiles of Leading Antisense and RNAi Therapeutics Companies. PLUSCOVID-19 Recovery Scenarios.
Global Antisense and RNAi Therapeutics Market was valued at US$XX billion in 2021 and is projected to reach a market value of US$ XX billion by 2031. The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market. Increasing collaborations among bio-pharmaceutical companies and Increasing pipeline product portfolio are some of the factors driving the growth of Antisense and RNAi Therapeutics market.
COVID-19 Impact on the Global Antisense and RNAi Therapeutics Market
The COVID-19 pandemic is caused due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2. The need to develop significant and effective therapeutics is increasing. However, the innate RNA interference (RNAi) mechanism enables to develop front line therapies to prevent from virus. Through specific binding approach and therapeutic targets by using short interfering RNA (siRNA) and short hairpin RNA (shRNA) molecules. However, Pfizer Inc. and BioNTech SE submitted amended protocol to the U.S. Food and Drug Administration to enhance phase-3 pivotal COVID-19 vaccine trial. The companies are collaborating to combat & develop COVID-19 vaccine, BNT162 mRNA vaccine program, and modRNA candidate BNT162b2.
Technological advancements and innovation
Various molecular technologies are intended to regulate gene expression, are developed recently as strategy to combat inflammatory and neoplastic diseases. The antisense technology has rapid, specific, significant approach to inhibit gene expression through recognition of cellular RNAs. However, the advancement in human genome sequencing, rational design of oligonucleotides, theoretical easiness, and affordable costs of compounds led to use them as therapeutic agents or tools to assess gene function.
Increasing collaborations among bio-pharmaceutical companies
In October 2018, Arrowhead pharmaceutics entered into a license agreement with Janssen Pharmaceuticals, Inc., (Johnson & Johnson) to develop and commercialize ARO-HBV. In April 2019, the company presented clinical data from an ongoing Phase 1/2 study (AROHBV1001) of JNJ-3989 (formerly ARO-HBV). The RNAi therapeutic are considered as the potential treatment for patients with chronic hepatitis B virus infection. It was presented at the International Liver Congress2019 (ILC), the annual meeting of the European Association for the Study of the Liver (EASL). However, the increasing collaboration among the companies are boosts the global antisense & RNAi therapeutics market.
Rising approval &drug launch of RNA therapeutics plays significant role in the growth of the market.
The European Medicines Agency has suggested approval for Alnylam’s Givlaari (givosiran) for acute hepatic porphyria (AHP). The (RNAi) drug is approved in European Union and the United States to treat AHP, which is rare and life-threatening genetic condition. The ONPATTRO (patisiran) received US FDA approval for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (HATTR) in adults. The increasing approval & regular product launches for the antisense & RNAi therapeutics further creates opportunity for the market.
Tekmira Pharmaceuticals, Ionis Pharmaceuticals, Glaxo Smith Kline, Alnylam Pharmaceuticals Inc., Antisense Therapeutics, Sanofi-Genzyme, Silence Therapeutics, F. Hoffmann-La Roche Ltd, Sirnaomics Inc., Gene Signal, BioNTech, Quark Pharmaceuticals, CureVac AGare some of the key players contributing to the growth of the global Antisense and RNAi Therapeutics market. The market players are adopting new strategies to stay competitive in the global market such as new product developments, joint ventures, mergers and acquisitions, and geographical expansions.
In April 2018, Arbutus Biopharma Ltd with Roivant launched Genevant Sciences, which enables in discovery, development, and commercialization of RNA-based therapeutics. The company received licensed exclusive rights to its LNP and ligand conjugate delivery platforms to Genevant for RNA-based applications outside of Hepatitis B virus.
In August 2020, Alnylam Pharmaceutics Inc. received United States Food and Drug Administration (FDA) approval of an RNAi Therapeutic, ONPATTRO (patisiran), to treat polyneuropathy of hereditary transthyretin-mediated amyloidosis (HATTR) in adults. The approval enables to treat hATTR amyloidosis, which is rare, inherited, life-threatening disease. The hATTR amyloidosis may lead to other significant disabilities such as decreased ambulation with the loss of the ability to walk unaided, a reduced quality of life, and a decline in cardiac functioning.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
14 July 2021
Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.